Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8166194 | 1.00 | REN (0.76) | RENCYP3A4 | |
| SCHEMBL3116153 | 1.00 | REN (0.76) | RENCYP3A4 | |
| SCHEMBL13249791 | 0.95 | REN (0.69) | RENCYP3A4 | |
| SCHEMBL3117832 | 0.95 | REN (0.69) | RENCYP3A4 | |
| SCHEMBL13250002 | 0.95 | REN (0.75) | RENCYP3A4 | |
| SCHEMBL8156802 | 0.95 | REN (0.75) | RENCYP3A4 | |
| SCHEMBL3109723 | 0.94 | REN (0.76) | RENCYP3A4 | |
| SCHEMBL3115653 | 0.94 | REN (0.76) | RENCYP3A4 | |
| SCHEMBL8155095 | 0.94 | REN (0.76) | RENCYP3A4 | |
| SCHEMBL8156835 | 0.94 | REN (0.67) | RENCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179109-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2010-07-15 | — | — | US | disclosed |
| US-20100179109-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2010-07-15 | — | — | US | disclosed |
| US-20090275581-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090275581-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090264428-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264428-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| WO-2008124575-A1 | RENIN INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2007117482-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179109-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | REN 1/4885CYP3A4 2462/4885 |
| US-20090275581-A1 | RENIN INHIBITORS | REN, ACE, SERPINB1 | REN 1/4885CYP3A4 1612/4885 |
| US-20090264428-A1 | Renin Inhibitors | REN, ACE, SERPINB1 | REN 1/4885CYP3A4 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.